Zheng Wrigley Field to NASDAQ OMX and fully anticipate thather

Zheng updates about wrigley field to NASDAQ arena field fells in OMX and fully anticipate thather extensive experience in China will provide direction to companies looking tolist with the world's largest exchange company," said Bob McCooey, Senior VicePresident of New Listings and Capital Markets, NASDAQ OMX.Prior to the NYSE, Ms. Prior to joining NASDAQ OMX, Zheng was anExecutive Director for NYSE Euronext."We are delighted to welcome Ms. In addition, she will work closely with the relevant governmentand regulatory bodies in China. Yeeli Hua Zheng has joined NASDAQ OMX asthe Chief Representative in China with the primary responsibility of servingNASDAQ's listed Chinese companies and assisting other Chinese companies with aNASDAQ listing. NEW YORK, July 24, 2009 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc.(Nasdaq:NDAQ) today announced that Ms. NeurogesXdisclaims any intent or obligation to update these forward-looking statements,and claims the protection of the Safe Harbor for forward-looking statementscontained in the Act. For further information regardingthese and other risks related to NeurogesX' business, investors should consultNeurogesX' filings with the Securities and Exchange Commission NeurogesX, Inc.

The company has evaluatedthese compounds in vitro and in vivo and is currently seeking developmentpartners for these programs.Safe Harbor StatementThis press release contains forward-looking statements for purposes of thePrivate Securities Litigation Reform Act of 1995 (the "Act") address for wrigley field . NGX-1998has completed three Phase 1 studies and NeurogesX is currently evaluating thetiming of entering Phase 2 development.NeurogesX' early stage product pipeline includes pre-clinical compounds, whichare prodrugs of acetaminophen and various opioids authentic stadium seats . NeurogesX submitted a new drug application (NDA) for PHN to the U.S ballpark field . Food andDrug Administration (FDA) which was accepted for filing by the FDA in December2008 and was given a Prescription Drug User Fee Act (PDUFA) date of August 16,2009.NeurogesX' second most advanced product candidate, NGX-1998, is a topicallyapplied, liquid formulation containing a high concentration of capsaicindesigned to treat pain associated with neuropathic pain conditions baseball . NeurogesX' late stage product portfolio is led by itsproduct candidate Qutenza, a dermal patch designed to manage pain associatedwith peripheral neuropathic pain conditions. Qutenza is currently approved inthe European Union for the treatment of neuropathic pain in non-diabeticadults, either alone or in combination with other medicinal products for pain. NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developingand commercializing novel pain management therapies.

Its initial focus is onchronic peripheral neuropathic pain, including postherpetic neuralgia (PHN),painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabeticneuropathy (PDN) address of wrigley field . The impact on the agency's timing, if any, foran ultimate decision on the NDA is not yet known Dr arena field . Jeffrey Tobias, NeurogesX' Chief Medical Officer commented, "I am gratefulto our clinical investigators and the entire NeurogesX team for workingtogether to quickly complete this study authentic stadium seats . We believe that these results willaddress the FDA's questions relating to the use of an FDA-approved topicalanesthetic as part of the Qutenza treatment procedure."About NeurogesX, Inc .